Merck did not immediately respond to Reuters' request for a comment, while Eyebiotech declined to comment. Eyebiotech is a clinical stage opthalmology company, with operations in the U.S. and the UK, that seeks to treat patients with sight-threatening diseases. Its major drug in clinical stage, Restoret, aims to treat retinal diseases characterized by leakage that can lead to impaired vision.
美股在假期後先升後回,受惠英偉達上達1,100美元帶動,納斯達克指數曾歷史性突破17,000點以上,午市一度近抹去所有升幅,惟最終能守穩在心理關口收市;道瓊斯指數曾跌近300點,標普500指數則近平收。債市向下,美國國債拍賣需求弱,10年期國債息率升7點子以上。中東局勢升溫,紐約期油升2.7%。
Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC). The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant). The study met its overall survival (OS) endpoint.